BUSINESS

Stella Pharma Launches New Cancer Radiation Therapy Steboronine

May 20, 2020
Stella Pharma on May 20 rolled out Steboronine (borofalan (10B)), an agent used in a new type of cancer radiation therapy called boron neutron capture therapy (BNCT), for the treatment of head and neck cancer. BNCT combines a boron-based drug…

To read the full story

Related Article

BUSINESS

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

By Tatsuya Otsuka

Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…

By Philip Carrigan

Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…